STADE‐HF (sST2 As a help for management of HF): a pilot study

STADE‐HF (sST2 As a help for management of HF): a pilot study

Abstract Aims Biomarkers are not recommended until now to guide the management of patients with heart failure (HF). Soluble suppression of tumorigenicity 2 (sST2) appears as a promising biomarker. The current study considered pre‐discharged sST2 values as a guide for medical management in patients a...

Full description

Bibliographic Details
Main Authors: Fabien Huet, Jean Nicoleau, Anne‐Marie Dupuy, Corentin Curinier, Cyril Breuker, Audrey Castet‐Nicolas, Manuela Lotierzo, Eran Kalmanovich, Laetitia Zerkowski, Mariama Akodad, Jérôme Adda, Audrey Agullo, Florence Leclercq, Jean‐Luc Pasquie, Pascal Battistella, Camille Roubille, Pierre Fesler, Grégoire Mercier, Guillaume Bourel, Jean‐Paul Cristol, François Roubille
Format: Article
Language:English
Published: Wiley 2020-04-01
Series:ESC Heart Failure
Subjects:
Heart failure
Biomarkers
sST2
Readmission
Natriuretic peptide
Therapeutic
Online Access:https://doi.org/10.1002/ehf2.12663

Internet

https://doi.org/10.1002/ehf2.12663

Similar Items